Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix. doi: 10.1016/j.hoc.2008.07.002.

Diffuse large B-cell lymphoma.

Author information

1
James P. Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1-4118C, Rochester, NY 14642, USA. jonathan_friedberg@urmc.rochester.edu

Abstract

Diffuse large B-cell lymphoma (DLBCL) remains a curable lymphoma, with improved outcome resulting in large part from the incorporation of rituximab in standard regimens. The disease is heterogeneous clinically, morphologically, and molecularly. Recent insights into the molecular heterogeneity of DLBCL are beginning to yield novel therapeutics with significant promise for key subsets of patients. Although cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone chemotherapy with rituximab remains a standard therapeutic approach for most patients who have DLBCL, it is anticipated that novel agents will be included in treatment regimens for many patients in the near future.

PMID:
18954744
PMCID:
PMC2593154
DOI:
10.1016/j.hoc.2008.07.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center